Skip to main content Accessibility help
×
Home
  • Print publication year: 2015
  • Online publication date: November 2015

3 - Hormones in cancer

Summary

Introduction

Hormonal therapies are some of the oldest active systemic anti-cancer therapies in use today. In 1896, Beatson demonstrated that surgical oophorectomy resulted in tumour regression in some premenopausal women with metastatic breast cancer, and, by doing so, he was the first to identify a link between ovarian function and breast cancer (Beatson, 1896).

Substantial evidence now exists that hormones play a key role in both the cause and the outcome of several cancers. Although this is most clearly seen in breast and prostate cancer, other cancers that may exhibit hormone dependence include endometrial, ovarian and testicular cancers.

Hormones are classified into two groups:

• non-steroidal hormones including peptides, polypeptides or derivatives of amino acids, generally acting via cell-membrane-localised receptors which trigger second messengers within the cytoplasm; and

• steroidal hormones, such as oestrogens, androgens and progestins, bind to intracellular receptors to mediate their action.

This chapter will focus primarily on steroidal hormones that are of particular importance in breast and prostate cancer: oestrogens, progestins and androgens. It should be read in conjunction with the relevant site-specific chapters (Chapters 19 and 22). This chapter provides some background knowledge of the production and functioning of hormones and their receptors, which will help in the understanding of commonly used therapies. The aetiology of hormone-related cancers is discussed in the relevant site-specific chapters.

Steroidal hormones have the potential to activate oncogenes or inactivate tumour-suppressor genes, producing a sequence of changes within the cell that ultimately lead to cancer. The continued growth of the cancer often depends on continuing hormone stimulation and so removing the hormonal stimulus causes the cancer to regress. Anti-cancer hormone therapies work in a number of different ways – by affecting hormone synthesis, metabolism or action, or by altering hormone receptor expression within the cell.

A summary of the major historical landmarks in anti-cancer hormonal therapy since Beatson's observation in 1896 is listed here.

Anonymous, . (1997). Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br. J. Urol., 79, 235–246.
Armstrong, J. G., Gillham, C. M. and Dunne, M. T. (2011). A randomized trial (Irish Clinical Oncology Research Group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 81, 35–45.
Beatson, G. T. (1896). On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet, ii, 104–107.
Bliss, J., Kilburn, L. S., Coleman, R. E., et al. (2012). Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study. J. Clin. Oncol., 30, 709–717.
Boccardo, F., Rubagotti, A., Battaglia, M., et al. (2005). Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J. Clin. Oncol., 23, 808–815.
Bolla, M., Gonzalez, D., Warde, P., et al. (1997). Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med., 337, 295–300.
Bolla, M., Collette, L., Blank, L., et al. (2002). Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet, 360, 103–106.
Bolla, M., de Reijke, T. M., Van Tienhoven, G., et al. (2009). Duration of androgen suppression in the treatment of prostate cancerN. Engl. J. Med., 360, 2516–2527.
Crook, J. M., Ludgate, C., Malone, S., et al. (2009). Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 73, 327–333.
Crook, J. M., O'Callaghan, C. J., Duncan, G, et al. (2012). Intermittent androgen suppression for rising PSA level after radiotherapy. N. Engl. J. Med., 367, 895–903.
Cuzick, J., Sestak, I, Baum, M., et al. (2010). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10 year analysis of the ATAC trial. Lancet Oncol., 11, 1135–1141.
Cuzick, J., Sestak, I. and Forbes, J. F. (2014). Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet, 383, 1041–1048.
D'Amico, A. V., Kantoff, P., Loffredo, M., et al. (2006). Predictors of mortality after prostate-specific antigen failure. Int. J. Radiat. Oncol. Biol. Phys., 65, 656–660.
D'Amico, A. V., Denham, J. W., Crook, J. M., et al. (2007). Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J. Clin. Oncol., 25, 2420–2425.
D'Amico, A. V., Chen, M-H., Renshaw, A. A., et al. (2008). Androgen suppression and radiation vs radiation alone for prostate cancer. J. Am. Med. Ass., 299, 289–295.
Davis, C., Pan, H., Godwin, J., et al. (2013). Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet, 381, 805–816.
Denham, J. W., Steigler, A. and Lamb, D. S. (2011). Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol., 12, 451–459.
Dowsett, M., Cuzick, J., Wale, C., et al. (2005). Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J. Clin. Oncol., 23, 7512–7517.
EBCTCG. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365, 1687–1717.
EBCTCG. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378 , 771–784.
Fellows, G. J., Clark, P. B., Beynon, L. L., et al. (1992). Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council Study. Urological Cancer Working Party – Subgroup on Prostatic Cancer. Br. J. Urol., 70, 304–309.
Fisher, B., Costantino, J., Redmond, C., et al. (1989). A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have oestrogen-receptor-positive tumors. N. Engl. J. Med., 320, 479–484.
Fizazi, K., Scher, H., Molina, A., et al. (2012). Abiraterone acetate for the treatment of metastatic castrate-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol., 13, 983–992.
Gray, R. G., Rea, D., Handley, K., et al. (2013). aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer. J Clin Oncol., 31 (Suppl.), abstr. 5.
Horwitz, E. M., Bae, K., Hanks, G. E., et al. (2008). Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J. Clin. Oncol., 26, 2497–2504.
Hopp, T. A., Weiss, H. L., Hilsenbeck, S. G., et al. (2004). Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival states. Clin. Cancer Res., 10, 2751–2760.
Howell, A., Cuzick, J., Baum, M., et al. (2005). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet, 365, 60–62.
Huggins, C. and Bergenstal, D. M. (1952). Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res., 12, 134–141.
Huggins, C. and Hodges, C. V. (1941). Studies on prostate cancer. The effects of castration, of oestrogen and of androgen injection on serum phosphatases in carcinoma of the prostate. Cancer Res., 1, 293–297.
Hussain, S. A., Weston, R., Stephenson, R. N., et al. (2003). Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int., 92, 690–694.
Hussain, S. A., Tangen, C. M., Berry, D. L., et al. (2013). Intermittent versus continuous androgen deprivation therapy in prostate cancer. N. Engl. J. Med., 368, 1314–1325.
Iversen, P., Tyrrell, C. J., Kaisary, A. V., et al. (2000). Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J. Urol., 164, 1579–1582.
Jin, H., Tu, D., Zhao, N.,et al. (2012). Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover. J. Clin. Oncol., 30, 718–721.
Joerger, M. and Thurlimann, B. (2009). Update of the BIG 1–98 trial: where do we stand?Breast, 18, 78–82.
Jones, C. U., Hunt, D., McGowan, D. G., et al. (2011). Radiotherapy and short-term androgen deprivation for localized prostate cancer. N. Engl. J. Med., 365, 107–118.
Laverdiere, J., Nabid, A., De Bedoya, L. D., et al. (2004). The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2–T3 prostate cancer. J. Urol., 171, 1137–1140.
McLeod, D. G., Iversen, P., See, W. A., et al. (2006). Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int., 97, 247–254.
Messing, E. M., Manola, J., Yao, J., et al. (2006). Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol., 7, 472–479.
Milano, A., Dal Lago, L., Sotiriou, C., et al. (2006). What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur. J. Cancer, 42, 2692–2705.
Miller, W. R., Anderson, T. J., Dixon, J. M., et al. (2006). Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment. Br. J. Cancer, 94, 1333–1338.
Noble, R. L. (1980). Production of Nb rat carcinoma of the dorsal prostate and response of estrogen-dependent transplants to sex hormones and tamoxifen. Cancer Res., 40, 3547–3550.
Perdona, S., Autorino, R., De Placido, S., et al. (2005). Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol., 6, 295–300.
Pilepich, M. V., Winter, K., Lawton, C. A., et al. (2005). Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85–31. Int. J. Radiat. Oncol. Biol. Phys., 61, 1285–1290.
Roach, M. 3rd, Bae, K. and Speight, J. (2008). Short-term neoadjuvant androgen deprivation therapy and external beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J. Clin. Oncol. Biol. Phys., 26, 585–591.
Rodrigues, N. A., Chen, M. H., Catalona, W. J., et al. (2006). Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer. Cancer, 107, 514–520.
Ryan, C. J., Smith, M., de Bono, J. S., et al. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med., 368, 138–148.
Scher, H., Fizazi, K., Saad, F., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med., 367, 1–11.
Schmitt, B., Bennett, C., Seidenfeld, J., et al. (2000). Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst. Rev., 2, CD001526.
See, W. A. and Tyrrell, C. J. (2006). The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J. Cancer Res. Clin. Oncol., 132 (Suppl. 13), 7–16.
Shahinian, V. B., Kuo, Y. F., Freeman, J. L., et al. (2005). Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med., 352, 154–164.
Smith, I. E., Dowsett, M., Yap, Y. S., et al. (2006). Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J. Clin. Oncol., 24, 2444–2447.
Smith, M. R., Eastham, J., Gleason, D. M., et al. (2003). Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J. Urol., 169, 2008–2012.
Tyrrell, C. J., Payne, H., See, W. A., et al. (2005). Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother. Oncol., 76, 4–10.
Vogel, V. G. (2009). The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert. Rev. Anticancer Ther., 9, 51–60. Erratum in Expert. Rev. Anticancer Ther., 9, 388.
Wirth, M. P., See, W. A., McLeod, D. G., et al. (2004). Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J. Urol., 172(5 Pt. 1), 1865–1870.
Zelefsky, M. J. and Harrison, A. (1997). Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology, 49 (Suppl. 3A), 38–45.
Zondek, B. (1940). Effect of prolonged administration of oestrogen on uterus and anterior pituitary of human beings. J. Am. Med. Ass., 114, 1850–1854.